Valirx (VAL)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1.68p
   
  • Change Today:
      0.000p
  • 52 Week High: 11.25
  • 52 Week Low: 1.23
  • Currency: UK Pounds
  • Shares Issued: 132.35m
  • Volume: 84,491
  • Market Cap: £2.22m
  • RiskGrade: 435

Latest ShareCast News

ValiRx subsidiary makes first sale

By Josh White

Date: Monday 18 Nov 2024

(Sharecast News) - ValiRx, a life science company focussed on early-stage cancer therapeutics and women's health, announced the first sale from its wholly-owned subsidiary Inaphaea BioLabs on Monday.

ValiRx losses narrow in first half

By Josh White

Date: Friday 27 Sep 2024

(Sharecast News) - ValiRx, a life science company focussed on cancer therapeutic development, reported a total comprehensive loss of £0.97m for the six months ended 30 June on Friday, narrowing from a loss of £1.04m in the same period last year.

ValiRx pulls out of University of Barcelona collaboration

By Josh White

Date: Thursday 26 Sep 2024

(Sharecast News) - ValiRx said in an update on Thursday that it has concluded its evaluation project with the University of Barcelona, focussed on early-stage cancer therapeutics targeting the 'KRAS2' series of drug candidates.

ValiRx subsidiary inks agreement with research f... 18-Sep-2024 ShareCast
ValiRx inks deal with Dundee Drug Discovery Unit 12-Feb-2024 ShareCast
ValiRx enters option deal with Ambrose Healthcare 05-Dec-2023 ShareCast
ValiRx enters partnership with StingRay Bio 10-Nov-2023 ShareCast
ValiRx shares jump as H1 losses shrink 24-Aug-2023 ShareCast
ValiRx subsidiary Inaphaea signs deal with Agili... 14-Aug-2023 ShareCast
ValiRx terminates collaboration with Hokkaido Un... 16-Jun-2023 ShareCast
ValiRx acquires assets of in-liquidation Imagen ... 14-Jun-2023 ShareCast
ValiRx incorporates new wholly-owned lab subsidi... 01-Mar-2023 ShareCast
ValiRx forms new majority-owned breast cancer su... 24-Oct-2022 ShareCast
ValiRx expecting to grant extension of exclusivi... 17-Jun-2022 ShareCast
ValiRx amends longstanding licence deal with Can... 20-Dec-2021 ShareCast
ValiRx adds three new patents in first half 06-Jul-2021 ShareCast
ValiRx terminates peptide drug candidate deal 27-May-2021 ShareCast
Physiomics and ValiRx enter new collaboration deal 15-Feb-2021 ShareCast
ValiRx adds four new patents to portfolio in 2020 19-Jan-2021 ShareCast
ValiRx looks to build on portfolio of drug candi... 06-Jul-2020 ShareCast
 

Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Valirx Market Data

Currency UK Pounds
Share Price 1.68p
Change Today 0.000p
% Change 0.00 %
52 Week High 11.25
52 Week Low 1.23
Volume 84,491
Shares Issued 132.35m
Market Cap £2.22m
RiskGrade 435

Valirx Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
11.77% above the market average11.77% above the market average11.77% above the market average11.77% above the market average11.77% above the market average
20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average20.00% above the sector average
Price Trend
92.05% below the market average92.05% below the market average92.05% below the market average92.05% below the market average92.05% below the market average
87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average87.76% below the sector average
Income Not Available
Growth Not Available

Valirx Dividends

No dividends found

Trades for 21-Nov-2024

Time Volume / Share Price
16:26 3,649 @ 1.67p
15:50 17,126 @ 1.60p
13:42 1,000 @ 1.60p
11:51 50,000 @ 1.68p
11:46 11,414 @ 1.60p

Valirx Key Personnel

CFO Gerald Desler

Top of Page